A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis (PsO) every year in the United States, affecting 2.2% of the population. Approximately 80% of those affected have mild-to-moderate psoriasis, while 20% have moderate-to-severe psoriasis, which is often treated with immunology drugs.
SMi Group is proud to announce the return of the 9th annual Biosimilars and Biobetters conference, taking place on the 26th and 27th September 2018 in London, UK. Registration for the event is now open and the newly released brochure is available to download from the event website.
Celltrion has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin (trastuzumab).
Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced the presentation of two long-term, Phase III studies: one each for biosimilar Zessly® (infliximab) and biosimilar Erelzi® (etanercept).
Samsung Bioepis Co., Ltd. and Biogen recently announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI (SB4, etanercept biosimilar), FLIXABI (SB2, infliximab biosimilar), and IMRALDI (SB5, adalimumab biosimilar) – which will be presented at the Annual European Congress of Rheumatology (EULAR 2018) held June 13–16 in Amsterdam, Netherlands.
New data presented at the Annual European Congress of Rheumatology (EULAR 2018) show that the subcutaneous (SC) formulation of CT-P13 is comparable in terms of efficacy and safety with the intravenous (IV) formulation of CT-P13 for the treatment of patients with rheumatoid arthritis (RA) up to week 30.
ACON Investments ("ACON") announced today that affiliates of ACON Latin America Opportunities Fund IV, L.P., in partnership with Humus Capital Partners ("HCP"), a private equity firm based in Argentina, have acquired a majority equity interest in Biosidus S.A. and Biosidus Farma S.A. (collectively, "Biosidus" or the "Company"), Argentina's largest manufacturer and distributor of biosimilar pharmaceuticals with exports worldwide to more than 25 countries across four continents.
A new study released today by the Pacific Research Institute found that, by removing barriers holding back the increased use of biosimilars, savings could be significant. In a case study of infliximab, used to treat rheumatoid arthritis, Crohn's disease, and other illnesses, reforms could realize an annual savings of between $412 million and $465 million
Celltrion Healthcare recently presented new research at Digestive Disease Week (DDW) 2018, that shows the efficacy and safety of the CT-P13 subcutaneous (SC) formulation is comparable to the CT-P13 intravenous (IV) formulation up to week 30 in patients with active Crohn’s disease (CD).
Celltrion made an announcement that it will launch Bio CDMO (Contract Development and Manufacturing) business, in a bid to pursue open innovation for development of new drugs, at the 2018 BIO International Convention, the world’s premier life sciences event being held in Boston, June 4-7.
|
|
|
|
|
|
|
|
|